A Novel Rapamycin-polymer conjugate based on a new poly(Ethylene Glycol) multiblock copolymer

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 706-719

  Tai, Wanyi ^a   Chen, Zhijin ^a   Barve, Ashutosh ^a   Peng, Zhonghua ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

multiblock copolymer; PEG; polymer drug conjugate; rapalogue; rapamcyin

Indexed keywords

COPOLYMER; EVEROLIMUS; FLUORESCEIN ISOTHIOCYANATE; MACROGOL; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL TRANSPORT; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; ENDOCYTOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHILICITY; IC 50; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS; SIROLIMUS; SOLUBILITY;

EID: 84895483484     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1192-3     Document Type: Article

References (44)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721-6.
2. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst. 2001;93(20):1517-9.
3. Zhao H, Cui K, Nie F, Jin G, Li F, Wu L, et al. Effects of rapamycin on Breast Cancer cell migration through the cross-talk of MAPK pathway. Cancer Res. 2009;69(24 suppl).
4. Armstrong AJ et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010;16(11):3057-66.
5. Cloughesy TF et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8.
6. Phung TL et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10(2):159-70.
7. Bruns CJ et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res. 2004;10(6):2109-19.
8. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213(1-2):25-9.
9. Yatscoff R et al. Blood distribution of rapamycin. Transplantation. 1993;56(5):1202-6.
10. Ferron GM, Conway WD, Jusko WJ. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (rapamycin) determination. J Chromatogr B Biomed Sci Appl. 1997;703(1-2):243-51.
11. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603-16.
12. Sun M et al. The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems. Drug Dev Ind Pharm. 2011;37(8):986-94.
13. Gallant-Haidner HL et al. Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit. 2000;22(1):31-5.
14. Napoli KL et al. Distribution of sirolimus in rat tissue. Clin Biochem. 1997;30(2):135-42.
15. Yanez JA et al. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008;61(1):133-44.
16. Serkova N et al. Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 1997;10(12):1359-63.
17. Benjamin D et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868-80.
18. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19(56):6680-6.
19. Goudar RK et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005;4(1):101-12.
20. Fetterly GJ, Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, et al. Pharmacokinetics of oral deforolimus (AP23573, MK-8669). 2008 ASCO Annual Meeting, 2008.
21. Rubino JTS, Siskavich V, Harrison MM, Gandhi P. Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant. US Patent. 2011;8026276.
22. Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn. 2007;34(3):373-400.
23. Li C et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998;58(11):2404-9.
24. Li C et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol. 2000;46(5):416-22.
25. Sapra P et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008;14(6):1888-96.
26. Cheng J et al. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem. 2003;14(5):1007-17.
27. Ayral-Kaloustian S et al. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem. 2010;53(1):452-9.
28. Umeda N et al. A photocleavable rapamycin conjugate for spatiotemporal control of small GTPase activity. J Am Chem Soc. 2011;133(1):12-4.
29. Naicker S, Sharma SK,Thomas W. Rapamycin peptides conjugates: synthesis and uses thereof. Patent. 2004. US Patent: 7659244.
30. Agnihotri G et al. Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic gamma-glutamyldiaminopimelic acid derivatives. J Med Chem. 2011;54(5):1490-510.
31. Shaw C-C, Sellstedt J, Noureldin R, Cheal GK, Fortier G. Regioselective synthesis of rapamycin derivatives. 2001. US Patent 6,277,983.
32. Fajun Nan JD, Zuo J, Yu L, Meng L, Zhang Y, Yang N, et al. Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof. 2011. USPTO Applicaton No. 20110166172.
33. Bodanszky M, Bednarek MA, Bodanszky A. Coupling in the absence of tertiary amines. Int J Pept Protein Res. 1982;20(4):387-95.
34. Tai W et al. Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011;8(3):901-12.
35. Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989;49(16):4435-40.
36. Cheng J, Khin KT, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm. 2004;1(3):183-93.
37. Bhatt R et al. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J Med Chem. 2003;46(1):190-3.
38. Liu C-Y et al. New linearized relation for the universal viscosity - temperature behavior of polymer melts. Macromolecules. 2006;39(25):8867-9.
39. Decarie A et al. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol. 1996;271(4 Pt 2):H1340-7.
40. Chandran SS et al. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther. 2007;6(11):2928-37.
41. Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos. 1998;26(1):83-4.
42. Murthy N et al. Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J Control Release. 2003;89(3):365-74.
43. Sun Y et al. Intracellular labeling method for chip-based capillary electrophoresis fluorimetric single cell analysis using liposomes. J Chromatogr A. 2006;1135(1):109-14.
44. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-29.